Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY11.76 CNY
Change Today -0.01 / -0.08%
Volume 4.7M
600421 On Other Exchanges
As of 3:05 AM 04/2/15 All times are local (Market data is delayed by at least 15 minutes).

hubei yangfan holding co l-a (600421) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/15 - CNY12.05
52 Week Low
12/22/14 - CNY6.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HUBEI YANGFAN HOLDING CO L-A (600421)

Related News

No related news articles were found.

hubei yangfan holding co l-a (600421) Related Businessweek News

No Related Businessweek News Found

hubei yangfan holding co l-a (600421) Details

Hubei Yangfan Holding Co., Ltd. produces and distributes pharmaceutical products in China. The company’s principal pharmaceutical products include Gucining Capsules and Huoxue Tongmai Capsules. It also develops biological products, pharmaceuticals, environment-protection, and agricultural products, as well as related technologies. The company was formerly known as Wuhan National Pharmaceutical Technology Company Limited and changed its name to Hubei Yangfan Holding Co., Ltd. in April 2014. Hubei Yangfan Holding Co., Ltd. is headquartered in Wuhan, China.

hubei yangfan holding co l-a (600421) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hubei yangfan holding co l-a (600421) Key Developments

Hubei Yangfang Holding Co., Ltd. Provides Earnings Guidance for the Year 2014

Hubei Yangfang Holding Co., Ltd. provided earnings guidance for the year 2014. The company announced that according to preliminary statistics of its financial department, the company predicted that its net profit owned by shareholders of listed company in 2014 will be about between RMB 0.2 million and RMB 2.5 million, with a predicted year-on-year decrease of above 80% in business performance.

Hubei Yangfan Holding Co., Ltd., Board Meeting, Jan 23, 2015

Hubei Yangfan Holding Co., Ltd., Board Meeting, Jan 23, 2015. Agenda: To discuss and approve the proposal of adjusting depreciable life of machinery and equipment; to consider the proposal of holding subsidiary Shanghai Aobo Internal Combustion Engine Parts Co., Ltd. leasing formation workshop production factory and machinery and equipment from Shanghai Chongming Aoyan Internal-combustion Parts Co., Ltd.

Hubei Yangfan Holding Co., Ltd. to Report Q3, 2014 Results on Oct 30, 2014

Hubei Yangfan Holding Co., Ltd. announced that they will report Q3, 2014 results on Oct 30, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600421:CH CNY11.76 CNY -0.01

600421 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600421.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600421 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.8x
Price/Book 604.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HUBEI YANGFAN HOLDING CO L-A, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at